155 related articles for article (PubMed ID: 37169550)
1. Melanoma-related costs by disease stage and phase of management in Ireland.
Crealey GE; Hackett C; Harkin K; Heckmann P; Kelleher F; Lyng Á; McCarthy T; McEnery M; Meaney C; Roche D; Tobin AM
J Public Health (Oxf); 2023 Aug; 45(3):714-722. PubMed ID: 37169550
[TBL] [Abstract][Full Text] [Related]
2. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
3. Cost of care for colorectal cancer in Ireland: a health care payer perspective.
Tilson L; Sharp L; Usher C; Walsh C; S W; O'Ceilleachair A; Stuart C; Mehigan B; John Kennedy M; Tappenden P; Chilcott J; Staines A; Comber H; Barry M
Eur J Health Econ; 2012 Aug; 13(4):511-24. PubMed ID: 21638069
[TBL] [Abstract][Full Text] [Related]
4. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
5. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
[TBL] [Abstract][Full Text] [Related]
6. Cost of Cutaneous Melanoma by Tumor Stage: A Descriptive Analysis.
Serra-Arbeloa P; Rabines-Juárez ÁO; Álvarez-Ruiz MS; Guillén-Grima F
Actas Dermosifiliogr; 2017 Apr; 108(3):229-236. PubMed ID: 27887672
[TBL] [Abstract][Full Text] [Related]
7. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
McCullagh L; Walsh C; Barry M
Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
[TBL] [Abstract][Full Text] [Related]
8. Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model.
Vale L; Kunonga P; Coughlan D; Kontogiannis V; Astin M; Beyer F; Richmond C; Wilson D; Bajwa D; Javanbakht M; Bryant A; Akor W; Craig D; Lovat P; Labus M; Nasr B; Cunliffe T; Hinde H; Shawgi M; Saleh D; Royle P; Steward P; Lucas R; Ellis R
Health Technol Assess; 2021 Nov; 25(64):1-178. PubMed ID: 34792018
[TBL] [Abstract][Full Text] [Related]
9. Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Buja A; Sartor G; Scioni M; Vecchiato A; Bolzan M; Rebba V; Sileni VC; Palozzo AC; Montesco M; Del Fiore P; Baldo V; Rossi CR
Acta Derm Venereol; 2018 Feb; 98(2):218-224. PubMed ID: 29110018
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
[TBL] [Abstract][Full Text] [Related]
11. Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries.
Gogebakan KC; Mukherjee K; Berry EG; Sonmez K; Leachman SA; Etzioni R
Cancer; 2021 Aug; 127(16):2926-2933. PubMed ID: 33905529
[TBL] [Abstract][Full Text] [Related]
12. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.
Franken MG; Leeneman B; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; van der Veldt AAM; Westgeest HM; Wouters MWJM; Haanen JBAG; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100320. PubMed ID: 34856511
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma.
Salans M; Courtney PT; Yip A; Murphy JD
Cancer Med; 2021 Oct; 10(19):6618-6626. PubMed ID: 34402192
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.
Mulder EEAP; Smit L; Grünhagen DJ; Verhoef C; Sleijfer S; van der Veldt AAM; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100303. PubMed ID: 34781194
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
19. Modelling the healthcare costs of skin cancer in South Africa.
Gordon LG; Elliott TM; Wright CY; Deghaye N; Visser W
BMC Health Serv Res; 2016 Apr; 16():113. PubMed ID: 27039098
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a melanoma screening programme using whole disease modelling.
Buja A; Rivera M; Girardi G; Vecchiato A; Rebba V; Pizzo E; Sileni VC; Palozzo AC; Montesco M; Zorzi M; Sartor G; Scioni M; Bolzan M; Fiore PD; Bonavina MG; Rugge M; Baldo V; Rossi CR
J Med Screen; 2020 Sep; 27(3):157-167. PubMed ID: 31711359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
